膽囊收縮素在糖尿病并發膽囊結石中的地位與作用_《中國普外基礎與臨床雜志》

作者：

孫登群 , 孟翔凌

安徽醫科大學第一附屬醫院普外科三西病區(合肥230032);

關鍵詞：

膽囊收縮素受體糖尿病膽囊結石

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的探討膽囊收縮素（CCK）在糖尿病并發膽囊結石中的地位與作用。
方法復習近幾年的相關文獻并進行綜述。
結果CCK在體內分布廣泛，一方面通過引起糖尿病而促進膽囊結石的發生，另一方面其本身及其受體異常也可以引起膽囊結石，與CCK有關的基因異常可能是糖尿病和膽囊結石共同的病理基礎。
結論CCK在糖尿病并發膽囊結石的發病中具有重要作用，但仍需進行深入研究。

引用本文： 孫登群,孟翔凌. 膽囊收縮素在糖尿病并發膽囊結石中的地位與作用. 中國普外基礎與臨床雜志, 2006, 13(4): 406-408. doi: 復制

1.	[J]. Dig Dis Sci， 2004; 49(7-8)∶1342.
2.	[J]. Ann Surg， 2002; 235(6)∶842.
3.	[J]. J Gastroenterol, 2002; 37(14)∶102.
4.	Dig Dis Sci， 2003; 48(10)∶1944.
5.	[J]. Eur J Intern Med, 2002; 13(2)∶123.
6.	Pagliarulo M, Fornari F, Fraquelli M, et al. Gallstone disease and related risk factors in a large cohort of diabetic patients [J]. Dig Liver Dis， 2004; 36(2)∶130.
7.	Wang Y, Prpic V, Green GM, et al. Luminal CCKreleasing factor stimulates CCK release from human intestinal endocrine and STC1 cells [J]. Am J Physiol Gastrointest Liver Physid, 2002； 282(1)∶G16.
8.	Miyasaka K, Shinozaki H, Jimi A, et al. Amylase secretion from dispersed human pancreatic acini: neither cholecystokinin A nor cholecystokinin B receptors mediate amylase secretion in vitro [J]. Pancreas， 2002; 25(2)∶161.
9.	Kayacetin E, Kisakol G, Kaya A, et al. Realtime sonography for screening of gallbladder motility in diabetic patients: relation to autonomic and peripheral neuropathy [J]. Neuro Endocrinol Lett， 2003; 24(1-2)∶73.
10.	MathusVliegen EM, Van IerlandVan Leeuwen ML, Terpstra A. Determinants of gallbladder kinetics in obesity [J]. Dig Dis Sci， 2004; 49(1)∶9.
11.	Graewin SJ, Kiely JM, Lee KH, et al. Nonobese diabetic mice have diminished gallbladder motility and shortened crystal observation time [J]. J Gastrointest Surg， 2004; 8(7)∶824.
12.	Ruhl CE, Everhart JE. Association of diabetes, serum insulin, and Cpeptide with gallbladder disease [J]. Hepatology， 2000; 31(2)∶299.
13.	Sonobe K, Sakai T, Satoh M, et al. Control of gallbladder contractions by cholecystokinin through cholecystokininA receptors in the vagal pathway and gallbladder in the dog [J]. Regul Pept, 1995; 60(1)∶33.
14.	Kuntz E, Pinget M, Damge P. Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats [J]. JOP, 2004; 5(6)∶464.
15.	Graewin SJ, Lee KH, Kiely JM, et al. Gallbladder myocytes are short and cholecystokininresistant in obese diabetic mice [J]. Surgery， 2004; 136(2)∶431.
16.	Milewicz A, Mikulski E, Bidzinska B. Plasma insulin, cholecystokinin, galanin, neuropeptide Y and leptin levels in obese women with and without type 2 diabetes mellitus [J]. Int J Obes Relat Metab Disord, 2000; 24(6)∶S152.
17.	Guilmeau S, Buyse M, Tsocas A, et al. Duodenal leptin stimulates cholecystokinin secretion: evidence of a positive leptincholecystokinin feedback loop [J]. Diabetes， 2003; 52(7)∶1664.
18.	Inoue H, Iannotti CA, Welling CM, et al. Human cholecystokinin type A receptor gene: cytogenetic localization, physical mapping, and identification of two missense variants in patients with obesity and noninsulindependent diabetes mellitus (NIDDM) [J]. Genomics, 1997; 42(2)∶331.
19.	MarchalVictorion S, Vionnet N, Escrieut C, et al. Genetic, pharmacological and functional analysis of cholecystokinin1 and cholecystokinin2 receptor polymorphism in type 2 diabetes and obese patients [J]. Pharmacogenetics, 2002； 12(1)∶23.
20.	Takiguchi S, Takata Y, Takahashi N, et al. A disrupted cholecystokinin A receptor gene induces diabetes in obese rats synergistically with ODB1 gene [J]. Am J Physiol， 1998; 274(2 Pt 1)∶E265.
21.	Funakoshi A, Miyasaka K, Yamamori S, et al. Gene structure of human cholecystokinin (CCK) typeA receptor: body fat content is related to CCK typeA receptor gene promoter polymorphism [J]. FEBS Lett， 2000; 466(2-3)∶264.
22.	Bi S, Moran TH. Actions of CCK in the controls of food intake and body weight: lessons from the CCKA receptor deficient OLETF rat [J]. Neuropeptides， 2002; 36(2-3)∶171.
23.	劉立人, 慕海峰，王盛江，等. 谷氨酰胺、膽囊收縮素預防完全胃腸外營養期間膽汁淤積的作用 [J]. 中國普外基礎與臨床雜志， 2000； 7（2）∶76.
24.	Pellegrini CA, Lewin M, Patti MG, et al. Gallbladder filling and response to cholecystokinin are not affected by vagotomy [J]. Surgery, 1985; 98(3)∶452.
25.	Glasbrenner B, DominguezMunoz JE, Nelson DK, et al. Postprandial release of cholecystokinin and pancreatic polypeptide in health and in gallstone disease: relationships with gallbladder contraction [J]. Am J Gastroenterol， 1994; 89(3)∶404.
26.	陳瑞新，王志偉，黃健，等. CCK8 在膽石癥患者血漿中的水平變化及其臨床意義 [J]. 放射免疫學雜志， 2004； 17（5）∶337.
27.	Deshpande SB, Gupta NK, Shukla VK. Cholelithiatic human gallbladders in vitro fail to respond to cholecystokinin but are responsive to carbachol, histamine, or electrical stimulation.
28.	Kano M, Shoda J, Satoh S, et al. Increased expression of gallbladder cholecystokinin: a receptor in prairie dogs fed a highcholesterol diet and its dissociation with decreased contractility in response to cholecystokinin [J]. J Lab Clin Med， 2002; 139(5)∶285.
29.	Nakeeb A, Comuzzie AG, Martin L, et al. Gallstones: genetics versus environment.
30.	Miyasaka K, Takata Y, Funakoshi A. Association of cholecystokinin A receptor gene polymorphism with cholelithiasis and the molecular mechanisms of this polymorphism.
31.	Sato N, Miyasaka K, Suzuki S, et al. Lack of cholecystokininA receptor enhanced gallstone formation: a study in CCKA receptor gene knockout mice [J].
32.	Wang DQ, Schmitz F, Kopin AS, et al. Targeted disruption of the murine cholecystokinin1 receptor promotes intestinal cholesterol absorption and susceptibility to cholesterol cholelithiasis [J]. J Clin Invest, 2004; 114(4)∶521.
33.	Bucceri AM, Calogero AE, Brogna A. Gallbladder and gastric emptying: relationship to cholecystokininemia in diabetics.

1. [J]. Dig Dis Sci， 2004; 49(7-8)∶1342.
2. [J]. Ann Surg， 2002; 235(6)∶842.
3. [J]. J Gastroenterol, 2002; 37(14)∶102.
4. Dig Dis Sci， 2003; 48(10)∶1944.
5. [J]. Eur J Intern Med, 2002; 13(2)∶123.
6. Pagliarulo M, Fornari F, Fraquelli M, et al. Gallstone disease and related risk factors in a large cohort of diabetic patients [J]. Dig Liver Dis， 2004; 36(2)∶130.
7. Wang Y, Prpic V, Green GM, et al. Luminal CCKreleasing factor stimulates CCK release from human intestinal endocrine and STC1 cells [J]. Am J Physiol Gastrointest Liver Physid, 2002； 282(1)∶G16.
8. Miyasaka K, Shinozaki H, Jimi A, et al. Amylase secretion from dispersed human pancreatic acini: neither cholecystokinin A nor cholecystokinin B receptors mediate amylase secretion in vitro [J]. Pancreas， 2002; 25(2)∶161.
9. Kayacetin E, Kisakol G, Kaya A, et al. Realtime sonography for screening of gallbladder motility in diabetic patients: relation to autonomic and peripheral neuropathy [J]. Neuro Endocrinol Lett， 2003; 24(1-2)∶73.
10. MathusVliegen EM, Van IerlandVan Leeuwen ML, Terpstra A. Determinants of gallbladder kinetics in obesity [J]. Dig Dis Sci， 2004; 49(1)∶9.
11. Graewin SJ, Kiely JM, Lee KH, et al. Nonobese diabetic mice have diminished gallbladder motility and shortened crystal observation time [J]. J Gastrointest Surg， 2004; 8(7)∶824.
12. Ruhl CE, Everhart JE. Association of diabetes, serum insulin, and Cpeptide with gallbladder disease [J]. Hepatology， 2000; 31(2)∶299.
13. Sonobe K, Sakai T, Satoh M, et al. Control of gallbladder contractions by cholecystokinin through cholecystokininA receptors in the vagal pathway and gallbladder in the dog [J]. Regul Pept, 1995; 60(1)∶33.
14. Kuntz E, Pinget M, Damge P. Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats [J]. JOP, 2004; 5(6)∶464.
15. Graewin SJ, Lee KH, Kiely JM, et al. Gallbladder myocytes are short and cholecystokininresistant in obese diabetic mice [J]. Surgery， 2004; 136(2)∶431.
16. Milewicz A, Mikulski E, Bidzinska B. Plasma insulin, cholecystokinin, galanin, neuropeptide Y and leptin levels in obese women with and without type 2 diabetes mellitus [J]. Int J Obes Relat Metab Disord, 2000; 24(6)∶S152.
17. Guilmeau S, Buyse M, Tsocas A, et al. Duodenal leptin stimulates cholecystokinin secretion: evidence of a positive leptincholecystokinin feedback loop [J]. Diabetes， 2003; 52(7)∶1664.
18. Inoue H, Iannotti CA, Welling CM, et al. Human cholecystokinin type A receptor gene: cytogenetic localization, physical mapping, and identification of two missense variants in patients with obesity and noninsulindependent diabetes mellitus (NIDDM) [J]. Genomics, 1997; 42(2)∶331.
19. MarchalVictorion S, Vionnet N, Escrieut C, et al. Genetic, pharmacological and functional analysis of cholecystokinin1 and cholecystokinin2 receptor polymorphism in type 2 diabetes and obese patients [J]. Pharmacogenetics, 2002； 12(1)∶23.
20. Takiguchi S, Takata Y, Takahashi N, et al. A disrupted cholecystokinin A receptor gene induces diabetes in obese rats synergistically with ODB1 gene [J]. Am J Physiol， 1998; 274(2 Pt 1)∶E265.
21. Funakoshi A, Miyasaka K, Yamamori S, et al. Gene structure of human cholecystokinin (CCK) typeA receptor: body fat content is related to CCK typeA receptor gene promoter polymorphism [J]. FEBS Lett， 2000; 466(2-3)∶264.
22. Bi S, Moran TH. Actions of CCK in the controls of food intake and body weight: lessons from the CCKA receptor deficient OLETF rat [J]. Neuropeptides， 2002; 36(2-3)∶171.
23. 劉立人, 慕海峰，王盛江，等. 谷氨酰胺、膽囊收縮素預防完全胃腸外營養期間膽汁淤積的作用 [J]. 中國普外基礎與臨床雜志， 2000； 7（2）∶76.
24. Pellegrini CA, Lewin M, Patti MG, et al. Gallbladder filling and response to cholecystokinin are not affected by vagotomy [J]. Surgery, 1985; 98(3)∶452.
25. Glasbrenner B, DominguezMunoz JE, Nelson DK, et al. Postprandial release of cholecystokinin and pancreatic polypeptide in health and in gallstone disease: relationships with gallbladder contraction [J]. Am J Gastroenterol， 1994; 89(3)∶404.
26. 陳瑞新，王志偉，黃健，等. CCK8 在膽石癥患者血漿中的水平變化及其臨床意義 [J]. 放射免疫學雜志， 2004； 17（5）∶337.
27. Deshpande SB, Gupta NK, Shukla VK. Cholelithiatic human gallbladders in vitro fail to respond to cholecystokinin but are responsive to carbachol, histamine, or electrical stimulation.
28. Kano M, Shoda J, Satoh S, et al. Increased expression of gallbladder cholecystokinin: a receptor in prairie dogs fed a highcholesterol diet and its dissociation with decreased contractility in response to cholecystokinin [J]. J Lab Clin Med， 2002; 139(5)∶285.
29. Nakeeb A, Comuzzie AG, Martin L, et al. Gallstones: genetics versus environment.
30. Miyasaka K, Takata Y, Funakoshi A. Association of cholecystokinin A receptor gene polymorphism with cholelithiasis and the molecular mechanisms of this polymorphism.
31. Sato N, Miyasaka K, Suzuki S, et al. Lack of cholecystokininA receptor enhanced gallstone formation: a study in CCKA receptor gene knockout mice [J].
32. Wang DQ, Schmitz F, Kopin AS, et al. Targeted disruption of the murine cholecystokinin1 receptor promotes intestinal cholesterol absorption and susceptibility to cholesterol cholelithiasis [J]. J Clin Invest, 2004; 114(4)∶521.
33. Bucceri AM, Calogero AE, Brogna A. Gallbladder and gastric emptying: relationship to cholecystokininemia in diabetics.

《中國普外基礎與臨床雜志》

膽囊收縮素在糖尿病并發膽囊結石中的地位與作用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

膽囊收縮素在糖尿病并發膽囊結石中的地位與作用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料